Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01362257
First received: May 26, 2011
Last updated: September 1, 2011
Last verified: August 2011

May 26, 2011
September 1, 2011
April 2011
June 2011   (final data collection date for primary outcome measure)
  • AUC(0-∞), AUC(0-t), Cmax, tmax, λz and t1/2 of total drug-related material (radioactivity) and GSK573719 in plasma following intravenous and oral dosing [ Time Frame: up to 8 days post-dose ] [ Designated as safety issue: No ]
    AUC(0-∞) = area under concentration time curve from time zero extrapolated to infinite time. AUC(0-t) = Area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration within a subject across all treatments. Cmax = Maximum observed concentration. tmax = Time of occurrence of Cmax. λz = Terminal phase rate constant. t1/2 = Terminal phase half life.
  • Urinary and faecal cumulative excretion as a percentage of the total radioactive dose administered over time [ Time Frame: up to 14 days post dose ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01362257 on ClinicalTrials.gov Archive Site
  • Oral F (absolute bioavailability) [ Time Frame: up to 8 days post dose ] [ Designated as safety issue: No ]
  • AUClast for oral dose, volume and clearance for intravenous dose [ Time Frame: up to 8 days post dose ] [ Designated as safety issue: No ]
    AUC = Area under concentration-time curve
  • Characterisation and quantification of metabolites in plasma, urine, duodenal bile and faecal homogenates to be documented and performed by DMPK, GSK and the results will be reported in a separate report [ Time Frame: up to 14 days post dose ] [ Designated as safety issue: No ]
  • Blood: plasma ratio of total drug related material (radioactivity) [ Time Frame: up to 8 days post dose ] [ Designated as safety issue: No ]
  • Spontaneous AE reporting, 12-lead ECG, vital signs and safety laboratory tests [ Time Frame: up to 14 days post dose ] [ Designated as safety issue: No ]
  • Oral F (absolute bioavailability) [ Time Frame: up to 8 days post dose ] [ Designated as safety issue: No ]
  • AUClast for oral dose, volume and clearance for intravenous dose [ Time Frame: up to 8 days post dose ] [ Designated as safety issue: No ]
    AUC = Area under concentration-time curve
  • Characterisation and quantification of metabolites in plasma, urine, duodenal bile and faecal homogenates to be documented and performed by DMPK, GSK and the results will be reported in a separate report [ Time Frame: up to 14 days post dose ] [ Designated as safety issue: No ]
  • Blood: plasma ratio of total drug related material (radioactivity) [ Time Frame: up to 8 days post dose ] [ Designated as safety issue: No ]
  • Spontaneous AE reporting, 12-lead ECG, vital signs and saftey laboratory tests [ Time Frame: up to 14 days post dose ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719
An Open-label, Two Period Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719, Administered as Single Dose of an Oral Solution and an Intravenous Infusion, to Healthy Male Adults

This will be a two-period, open-label study conducted at a single site. Six healthy male subjects will participate in the study to ensure at least four fully evaluable subjects. Each subject will receive a single 1000 μg (microgram) oral dose containing 50 μCi (Micro Curie) of [14C]-GSK573719 and a 65 μg intravenous infusion containing 7.1 μCi of [14C]-GSK573719. Whilst subjects are in-house, urine and faecal samples will be collected for a minimum of 168 hours (7 days) after dosing or for up to 240 hours (10 days) depending on the amounts of radioactivity still being excreted after Day 5. Faecal sample collection may continue at home for up to 14 days. Bile samples will be collected using Entero-Test string sampling of duodenal bile. Whole blood and plasma samples will be collected at various sample times after dosing to measure parent drug (plasma only) and total radiolabelled drug related material (blood and plasma). Urine and faeces aliquots will be taken to measure total radiolabelled drug-related material. Samples of urine, faeces and plasma will be transferred into a separate study to characterize and, where possible, quantify metabolites in these matrices.

This will be a single-centre, open-label, two period study in healthy male subjects. Each subject will participate in two separate dosing periods. In the first dosing period, each subject will receive a 65 μg single dose of intravenous infusion containing 7.1 μCi of [14C]-GSK573719 administered over 30 minutes. In the second dosing period, each subject will receive a single 1000 μg oral dose containing 50 μCi of [14C]-GSK573719. Each study period will involve an admission to the CRO (clinical research organisation) unit of between 7 and 10 days. The two dosing periods will be separated by a wash-out of at least 28 days between doses. Screening will occur within 30 days prior to the first dosing period. Each subject will be admitted to the clinical unit on the afternoon of Day -1. Whilst subjects are in-house, blood, urine and faecal samples will be collected for a minimum of 168 hours (7 days) after dosing or for up to 240 hours (10 days), depending on amounts of radioactivity still being excreted after day 5. Liquid scintillation counts (LSC) will be performed daily on the 24-hour urine pools and 24-hour faeces homogenates after Day 5 to measure total radioactivity concentrations. If less than 1% of the dose is excreted in each 24 hour period on Day 6 and Day 7 for a given subject, that subject will be discharged on Day 8, after the results of the LSC counts are available, and no further samples will be collected. If excretion is higher than 1%, or if the results are inconclusive, the subject will remain in-house, and urine and faecal collections will continue at 24 hour intervals, until excretion is less than 1% on Day 8, 9 or 10; again subjects will be discharged after the results of the LSC counts are available. On the morning of Day 11, all remaining subjects will be discharged from the clinic and subjects will be notified by phone as to whether they need to continue faecal collection at home. In the event that excretion is still higher than 1% upon discharge on Day 11, subjects will continue to collect faecal samples only, at home, at 24 hour intervals up to and including Day 14. Samples collected at home will be returned to the clinic every 2-3 days. The Entero-Test will be used in Treatment Period 1 only (IV dosing). The Entero-Test will be inserted at approximately 3.5 hours pre-dose while subjects are in a fasted state and removed at approximately 2.5 hours post-dose on day 1. At approximately 0.5 hours post-dose (i.e. two hours prior to string withdrawal) a food cue will be used to stimulate gall bladder emptying. Safety data collected will include spontaneous AE (adverse event) reporting, 12-lead ECG (electrocardiogram), vital signs, nursing/physician observation and safety laboratory tests. Subjects will complete follow up assessments within 8-12 days of their last dose (this may happen on the day of discharge from the unit). Final follow up contact will then be via telephone call to the subjects 2 to 3 days after final sample collection. The duration of the study will be approximately 11 to 12 weeks for each subject.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Pulmonary Disease, Chronic Obstructive
  • Drug: Treatment Period 1 - IV dose of GSK573719
    single dose of 65µg
  • Drug: Treatment Period 2 - Oral dose of GSK573719
    single dose of 1000µg
  • Experimental: 14C-GSK573719 Oral Solution
    single dose of 1000µg
    Intervention: Drug: Treatment Period 2 - Oral dose of GSK573719
  • Experimental: 14C-GSK573719 IV Solution
    single dose of 65µg
    Intervention: Drug: Treatment Period 1 - IV dose of GSK573719
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6
June 2011
June 2011   (final data collection date for primary outcome measure)

Inclusion:

AST (Aspartate aminotransferase), ALT (Alanine aminotransferase), alkaline phosphatase and bilirubin ≤ 1.5xULN (Upper limit of normal) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%) Healthy, non-smoking male subjects, 30-55 years old inclusive Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Section 8.1 Body Mass Index (BMI) within the range 18.5-29.0 kg/m2 (inclusive) Capable of giving written informed consent Average QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block Available to complete the study A history of regular bowel movements

Exclusion:

A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening A positive test for HIV (Human Immunodeficiency Virus) antibody Current or chronic history of liver disease, or known hepatic or biliary abnormalities Any clinically relevant abnormality identified on the screening medical assessment laboratory examination or 12-lead ECG (Electrocardiogram) Subjects with a positive urine test for drugs of abuse or alcohol at screening or prior to study medication administration Positive urine cotinine at screening History of regular alcohol consumption within 6 months of the study Treatment with an investigational drug within 60 days or 5 half-lives preceding the first dose of study medication Subjects who have had exposure to more than four new chemical entities within 12 months prior to the first dosing period Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days or 5 half-lives prior to the first dose of study medication Subjects who have received prescription medication within 14 days prior to the first dose of study drug. Subjects may still be entered into the study, if the prescription medication will not interfere with study procedures or compromise safety Donation of blood in excess of 500mL within 56 days prior to the first dose of study medication Participation in a clinical trial involving administration of 14C-labelled compound(s) within the last 12 months Subjects who have received a total body radiation dose of greater than 5.0 mSv or exposure to significant radiation in the 12 months prior to this study Previous history of active gastric or duodenal ulcer within 6 months prior to the first dose of study medication Any history of bleeding diathesis A pre-existing condition(s) interfering with normal gastrointestinal (GI) anatomy or motility or other GI dysfunction which may interfere with the absorption, distribution, metabolism or elimination of the study drug Surgical procedures on digestive tract An occupation which requires monitoring for radiation exposure, nuclear medicine procedures or excessive x-rays within the past 12 months History of anaphylaxis or anaphylactoid reactions, severe allergic responses to drugs History of sensitivity to any of the study medications Unwillingness or inability to follow the procedures outlined in the protocol Subject is mentally or legally incapacitated

Male
30 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT01362257
112014
No
Cheri Hudson; Clinical Disclosure Advisor, GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP